Navigation Links
Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
Date:6/16/2009

intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that dose-limiting toxicities may be experienced in future stages of the trial that will use higher doses of Cotara or the risk that results from larger trials may not be consistent with the results of earlier stage trials. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the quarter ended January 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contac
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
5. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
8. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
9. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. Promising Data ATIR Studies Presented by NIH Investigators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Quebec , November 21, 2014 ... como responsable comercial   Mariano Rodríguez es ...   KLOX está en marcha para comenzar ... de cura de heridas de reciente aprobación en Europa   ... "la compañía") se complace al anunciar los siguientes nombramientos: ...
(Date:11/21/2014)... Author Matthew J. Pallamary’s second short story ... published as a tribute to his mentor Ray ... Story” category of the 2014 USA Best Book ... USA Book News, said this year’s contest yielded over ... & Schuster, Penguin, John Wiley & Sons, Houghton Mifflin ...
(Date:11/21/2014)... 2014 BlueInGreen, LLC ( BlueInGreen® ... (Pinnacle), and PCI, Inc., leading suppliers of ozone ... been selected to provide a new state-of-the-art ozone ... R. Noland Wastewater Treatment. The new ozone ... gas dissolution technology, Pinnacle Ozone’s industry leading ...
(Date:11/21/2014)... Nov. 20, 2014 Polaris Group announced ... in its Phase 1 trial of ADI-PEG 20 ... treatment of malignant pleural mesothelioma (MPM) and non-squamous ... clinical trials on ADI-PEG 20, both as monotherapy ... treatment of several other indications, including breast cancer, ...
Breaking Biology Technology:KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... Regenicin™, Inc. (OTC Bulletin Board: ... that John J. Weber, the former highest ranking American ... USA"), has agreed to join the company as a ... Financial Officer.  Weber brings over 20 years of medical-related ...
... biomedical company advancing DNA-Guided Medicine, has been awarded ... Predicting Clinical Outcomes of Treatment in Patients ... Andreas Windemuth, Ph.D., Chief Technology Officer and ... has been successfully applied to several psychiatric and ...
... , Inc. (Nasdaq: GHDX ) today announced that ... conferences in September: Dean Schorno , ... Nicolaus Healthcare Conference 2010 on Friday, September 17 at 11:30 ... Genomic Health,s Chief Operating Officer and Chief Financial Officer, will ...
Cached Biology Technology:Former Fujifilm Medical Systems USA Executive John J. Weber Agrees to Join Regenicin™ as a Member of Its Board of Directors and Interim CFO 2Genomas Awarded US Patent for its PhyzioGenomics Platform Technology to Predict Treatment Responses 2Genomic Health to Present at Two Upcoming Investor Conferences 2
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
(Date:11/7/2014)... Nov. 7, 2014  In conjunction with the ... Departments, The Community Foundation of the Verdugos has announced the ... JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo Regional ... its first six months of existence, the Lab has processed ... for local law enforcement. "Because our number one ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... --- How do the French get away with a clean ... fats? Scientists have long suspected that the answer to the ... of a new study bring them closer to understanding why. ... Public Library of Science (PLoS) ONE, researchers from industry and ...
... York next week to discuss new approaches to one ... weather. Five years ago, Professor Peter Bernath, of ... the Atmospheric Chemistry Experiment (ACE) satellite mission. To ... University at the King,s Manor in York will review ...
... release is available in German . ... cormorants in order to reconcile nature conservation and fishing ... work at the European level, researchers from the Helmholtz ... journal Environmental Conservation. Furthermore, they suggest a five-step action ...
Cached Biology News:Substance in red wine found to keep hearts young 2Substance in red wine found to keep hearts young 3York symposium puts focus on chemical 'weather' 2The cormorant -- the 'black plague' or an example of successful species conservation? 2The cormorant -- the 'black plague' or an example of successful species conservation? 3The cormorant -- the 'black plague' or an example of successful species conservation? 4The cormorant -- the 'black plague' or an example of successful species conservation? 5
... cell and PowerPac basic power supply are used ... in agarose gels. The mini format cell includes ... and leveling bubble. The PowerPac basic power supply, ... V, 4-400 mA, and 75 W. Power cord ...
... The Sequi-Gen GT and PowerPac 3000 system, ... using a 38 x 30 cm vertical slab ... GT electrophoresis cell, which is capable of separating ... an integral plate chamber (IPC) assembly (IPC and ...
... Paragon CZE 2000 Capillary Electrophoresis System ... serum protein electrophoresis (SPE), urine protein ... fast and accurate analysis. The system ... sample preparation and no staining to ...
The filter 640DF35 for the Molecular Imager FX is a band pass filter for Texas Red dye....
Biology Products: